Glaucoma is a disease that is chronic in nature and indistinctive at an early stage, leading to late detection. It has become a major public health problem and a leading cause of irreversible blindness worldwide. The proton magnetic resonance spectroscopy (1H-MRS), of late, has been utilised to evaluate metabolites concentration in the brain, especially for detecting neurodegenerative disease. Considering that glaucoma is a neurodegenerative disease, studies on the concentration of metabolites using 1H-MRS in glaucoma patients could be investigated. This scoping review aims to examine the extent, range, and nature of studies on the 1H-MRS technique in glaucoma disease. The literature search was conducted using MEDLINE, CINAHL and SCOPUS, dated from 2000 until 2019. Studies on glaucoma using 1H-MRS were considered. Any processing method used to characterise the metabolite concentration generated by the 1H-MRS protocol has also been considered. Nine full-text studies were yielded after hundreds of literature identification, screening, and eligibility assessment. The included studies sought to determine the feasibility, change, and comparability of metabolite concentrations in glaucoma patients using 1HMRS with more studies utilising single-voxel spectroscopy (SVS) technique. The chosen anatomy of interest could have been influenced by several criteria, including the association between anatomy and the research query and the volume-sizing capabilities of the 1H-MRS technique. Six (6) metabolites were significantly identified, and quantified, including N-acetyl aspartate, Creatine, Choline, Myo-Inositol, Lactate and Glutamate-Glutamine. This scoping review points out the 1H-MRS application in different types and severity of glaucoma, highlighting the information on the type of patients, the detected metabolites in the anatomy involved, the 1H-MRS technique used and the raw data decipherment processing software. Future studies are needed to validate existing glaucoma studies and to explore the potential of detecting incipient glaucoma.

1. Abdull MM, Chandler C, Gilbert C. Glaucoma, “the silent thief of sight”: Patients’ perspectives and health seeking behaviour in Bauchi, northern Nigeria. BMC Ophthalmol. 2016;16(1):1–10. https://doi.org/10.1186/s12886-016-0220-6
2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. https://doi.org/10.1016/j.ophtha.2014.05.013
3. Barbosa-Breda J, Himmelreich U, Ghesquière B, Rocha-Sousa A, Stalmans I. Clinical metabolomics and glaucoma. Ophthalmic Res. 2018;59(1):1–6. https://doi.org/10.1159/000479158
4. Jones RS, Waldman AD. 1H-MRS evaluation of metabolism in Alzheimer’s disease and vascular dementia. Neurol Res. 2004;26(5):488–495. https://doi.org/10.1179/016164104225017640
5. Arksey H, O’Malley L. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32. https://doi.org/10.1080/1364557032000119616
6. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed1000097
7. Sidek S, Ramli N, Rahmat K, Ramli NM, Abdulrahman F, Kuo TL. In vivo proton magnetic resonance spectroscopy evaluation of metabolite concentration of optic radiation in primary open-angle glaucoma. Eur Radiol. 2016;26(12):4404–4412. https://doi.org/10.1007/s00330-016-4279-5
8. Guo L, Wang R, Tang Z, et al. Metabolic alterations within the primary visual cortex in early open-angle glaucoma patients: A proton magnetic resonance spectroscopy study. J Glaucoma. 2018;27(12):1046–1051. https://doi.org/10.1097/IJG.0000000000001098
9. Boucard CC, Hoogduin JM, van der Grond J, Cornelissen FW. Occipital proton magnetic resonance spectroscopy reveals normal metabolite concentrations in retinal visual field defects. PLoS One. 2007;2(2):e222. https://doi.org/10.1371/journal.pone.0000222
10. Aksoy DÖ, Umurhan Akkan JC, Alkan A, et al. Magnetic resonance spectroscopy features of the visual pathways in patients with glaucoma. Clin Neuroradiol. 2018:1–11. https://doi.org/10.1007/s00062-018-0728-7
11. Rucker JC, Biousse V, Mao H, et al. Detection of lactate in the human vitreous body using proton magnetic resonance spectroscopy. Arch Ophthalmol. 2003;121(6):909–911. https://doi.org/10.1001/archopht.121.6.909
12. Doganay S, Cankaya C, Alkan A. Evaluation of corpus geniculatum laterale and vitreous fluid by magnetic resonance spectroscopy in patients with glaucoma. Eye (Lond). 2012;26(8):1044–1051. https://doi.org/10.1038/eye.2012.84
13. Zhang Y, Chen X, Wen G, Wu G, Zhang X. Proton magnetic resonance spectroscopy reveals geniculocalcarine and striate area degeneration in primary glaucoma. PLoS One. 2013;8(8):e73197. https://doi.org/10.1371/journal.pone.0073197
14. Fiedorowicz M, Dyda W, Rejdak R, Grieb P. Magnetic resonance in studies of glaucoma. Med Sci Monit. 2011;17(10):RA227–RA232. https://doi.org/10.12659/msm.881973
15. Alfred AJ, Sulaiman FA, Shree D, Ahmed A, Saravanan K. Comparison of single voxel and multi voxel magnetic resonance spectroscopy in evaluation of brain tumors. Int J Contemp Med Surg Radiol. 2018;3(2):36–40. https://doi.org/10.21276/ijcmsr.2018.3.2.9
16. Yang ZX, Huo SS, Cheng XF, et al. Quantitative multivoxel proton MR spectroscopy study of brain metabolites in patients with amnestic mild cognitive impairment. Neuroradiology. 2011;54(5):451–458. https://doi.org/10.1007/s00234-011-0900-0
17. Ernst T, Chang L. Data processing and interpretation. In: ISMRM. 2006.
18. Blüml S. Magnetic resonance spectroscopy: Basic. In: Blüml S, Panigraphy A, eds. MR Spectroscopy of Pediatric Brain Disorders. Springer; 2013:11–23. https://doi.org/10.1007/978-1-4419-5864-8
19. Jansen JFA, Backes WH, Nicolay K, Kooi ME. 1H MR spectroscopy of the brain: Absolute quantification of metabolites. Radiology. 2006;240(2):318–332. https://doi.org/10.1148/radiol.2402050314